Alerts will be sent to your verified email
Verify Email
ALBERTDAVD
|
Albert David
|
Medicamen Biotech
|
Jenburkt Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
11.47 % | 8.49 % | 18.49 % |
|
5yr Avg Net Profit Margin
|
11.31 % | 10.0 % | 18.1 % |
|
Price to Book
|
1.18 | 2.2 | 2.92 |
|
P/E
|
73.9 | 49.41 | 15.48 |
|
5yr Avg Cash Conversion Cycle
|
-77.77 Days | 13.14 Days | -32.02 Days |
|
5yr Average Interest Coverage Ratio
|
93.73 | 10.36 | 87.2 |
|
5yr Avg ROCE
|
14.69 % | 12.12 % | 24.44 % |
|
5yr Avg Operating Profit Margin
|
9.55 % | 16.84 % | 22.46 % |
|
5 yr average Debt to Equity
|
0.02 | 0.14 | 0.02 |
|
5yr CAGR Net Profit
|
-4.92 % | -6.51 % | 14.21 % |
|
5yr Average Return on Assets
|
7.03 % | 5.75 % | 15.8 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
62.24 % | 40.46 % | 46.67 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.25 % | -3.14 % | 0.94 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Albert David
|
Medicamen Biotech
|
Jenburkt Pharma
|
|---|